FIELD: medicine.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns a form and a composition, containing amorphous VX-950, as well as application thereof in treating viral hepatitis type C.
EFFECT: applied invention provides high bioavailability of VX-950, and good storage stability of the composition.
70 cl, 14 ex, 10 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING HEPATITIS C | 2013 |
|
RU2665365C2 |
| STABILISED AMORPHOUS FORMS OF IMANITIB MESYLATE | 2008 |
|
RU2489149C2 |
| THE METHOD OF OBTAINING A PHARMACEUTICAL COMPOSITION WITH TACROLIMUS (VARIANTS) AND A PHARMACEUTICAL COMPOSITION OBTAINED BY THESE METHODS | 2022 |
|
RU2792098C1 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYLINDOL-1-YL)-ACETIC ACID | 2012 |
|
RU2616000C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES MEDIATED BY CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2015 |
|
RU2744460C2 |
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
| POLYMER COMPOSITIONS OF CETP INHIBITORS | 2007 |
|
RU2457841C2 |
| SOLID DISPERSION | 2012 |
|
RU2648448C2 |
| PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE AND IMPROVED PROCESSABILITY | 2014 |
|
RU2656662C2 |
